Asa L. Tapley

Infectious Disease
1959 NE Pacific St
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.

Journal: The Journal of infectious diseases
Published: May 08, 2025

Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination are Unaffected by Parasitemia in a Malaria-Endemic Setting.

Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination are Unaffected by Parasitemia in a Malaria-Endemic Setting.

Journal: medRxiv : the preprint server for health sciences
Published: May 05, 2025

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.

Journal: Nature communications
Published: April 09, 2025

Determining vaccine responders in the presence of baseline immunity using single-cell assays and paired control samples.

Determining vaccine responders in the presence of baseline immunity using single-cell assays and paired control samples.

Journal: Biostatistics (Oxford, England)
Published: March 30, 2025

Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.

Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.

Journal: EClinicalMedicine
Published: July 19, 2024

Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.

Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.

Journal: The Lancet. Infectious diseases
Published: March 07, 2024

High Asymptomatic Carriage With the Omicron Variant in South Africa.

High Asymptomatic Carriage With the Omicron Variant in South Africa.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 17, 2022

High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron.

High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron.

Journal: medRxiv : the preprint server for health sciences
Published: January 19, 2022

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Journal: Antimicrobial agents and chemotherapy
Published: March 31, 2018

Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.

Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.

Journal: The Journal of antimicrobial chemotherapy
Published: May 24, 2016

In vivo biosynthesis of terpene nucleosides provides unique chemical markers of Mycobacterium tuberculosis infection.

In vivo biosynthesis of terpene nucleosides provides unique chemical markers of Mycobacterium tuberculosis infection.

Journal: Chemistry & biology
Published: February 04, 2015

Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.

Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.

Journal: Antimicrobial agents and chemotherapy
Published: February 02, 2015
Showing 1-12 of 16

Last Updated: 09/26/2026